BioCentury
ARTICLE | Company News

Anaphore changes name, in-licenses anti-IL6 mAb

October 5, 2012 1:00 AM UTC

Anaphore Inc. (La Jolla, Calif.) changed its name to RuiYi Inc. on Thursday and announced a deal for exclusive, worldwide rights to a preclinical anti-IL-6 mAb from arGEN-X B.V. (Rotterdam, the Netherlands). RuiYi said the moves are part of the company's shift in strategy to discover and develop biologics in China, including mAbs that target GPCRs. The shift follows Anaphore's stock acquisition of RuiYi Biotechnology Inc. earlier this year. Anaphore was focused on developing Atrimers, drug candidates engineered from the human serum protein tetranectin. ...